Abstract:AMV@NanoCip, a novel biomimetic nanomedicine, integrates PBP2a antibody‐presenting nanovesicles with self‐assembled ciprofloxacin nanoparticles exhibiting sonodynamic properties. This formulation demonstrates exceptional MRSA‐targeting and antibacterial efficacy, achieving 99.99% sterilization in vitro and significant bacterial reduction in a pneumonia model. The sequential treatment strategy, combining adhesion, membrane disruption, and synergistic therapy, presents a promising approach for combating bacterial infections. Bacterial‐induced lower respiratory tract infections are a growing global health concern, exacerbated by the inefficacy of conventional antibiotics and delivery methods to effectively target the lower respiratory tract, leading to suboptimal therapeutic outcomes. To address this challenge, this work engineers PBP2a antibody‐presenting membrane nanovesicles (AMVs) specifically designed to target the penicillin‐binding protein variant on the surface of methicillin‐resistant Staphylococcus aureus (MRSA). Concurrently, this work develops pure ciprofloxacin nanoparticles (NanoCip) that, for the first time, exhibits exceptional self‐generated sonodynamic properties, attributed to hydrogen‐bond‐driven self‐assembly, while maintaining their inherent pharmacological efficacy. These NanoCip particles are integrated with AMVs to create a novel biomimetic nanomedicine, AMV@NanoCip. This formulation demonstrated remarkable MRSA‐targeting affinity in both in vitro and in vivo models, significantly enhancing antibacterial activity. Upon ultrasound stimulation, AMV@NanoCip achieves over 99.99% sterilization of MRSA in vitro, with a reduction exceeding 5.14 Log CFU. Prokaryotic transcriptomic analysis further elucidates the synergistic mechanisms by which AMV@NanoCip, coupled with ultrasound, disrupts the MRSA exoskeleton. In a MRSA‐induced pneumonia animal model, AMV@NanoCip+US results in a substantial bacterial load reduction in the lungs (99.99%, 4.02 Log CFU). This sequential treatment strategy (adhesion‐membrane disruption‐synergistic therapy) offers significant promise as an innovative therapeutic approach for combating bacterial infections.

Biocompatible formulation of a hydrophobic antimicrobial peptide L30 through nanotechnology principles and its potential role in mouse pneumonia model infected with Staphylococcus aureus

Turing cationic antimicrobial peptide KR-12 into Self-assembled nanobiotics with potent bacterial killing and LPS neutralizing activities

Enzyme-coated mesoporous silica nanoparticles as efficient antibacterial agents in vivo

Lung-Targeting Lysostaphin Microspheres for Methicillin-Resistant Staphylococcus Aureus Pneumonia Treatment and Prevention.

Injectable Phage-Loaded Microparticles Effectively Release Phages to Kill Methicillin-Resistant <i>Staphylococcus aureus</i>

Integration of Antimicrobial Peptides and Gold Nanorods for Bimodal Antibacterial Applications.

Infection Microenvironment-Responsive Multifunctional Peptide Coated Gold Nanorods For Bimodal Antibacterial Applications

Activities of a Broad-Spectrum Antimicrobial Peptide Analogue SAMP-A4-C8 and Its Combat Against Pneumonia in Staphylococcus Aureus-Infected Mice.

Turning cationic antimicrobial peptide KR-12 into self-assembled nanobiotics with potent bacterial killing and LPS neutralizing activities

Sono‐Triggered Biomimetically Nanoantibiotics Mediate Precise Sequential Therapy of MRSA‐Induced Lung Infection

Muco-adhesive Chitosan-Coated Polyphenol Nanoparticle for Treatment of Infectious Acute Pneumonia Through Sustained Pulmonary Delivery of Polymyxin B

Hydrogel Containing Nanoparticle-Stabilized Liposomes for Topical Antimicrobial Delivery

Albumin-Based LL37 Peptide Nanoparticles As a Sustained Release System Against Pseudomonas Aeruginosa Lung Infection

Inhalable Polymeric Microparticles for Phage and Photothermal Synergistic Therapy of Methicillin-Resistant Staphylococcus aureus Pneumonia

Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent

Inflammation-targeted nanoparticle with bacteria forced release of polymyxin B for pneumonia therapy

Lysgh15, A Novel Bacteriophage Lysin, Protects A Murine Bacteremia Model Efficiently Against Lethal Methicillin-Resistant Staphylococcus Aureus Infection

Use of the Antimicrobial Peptide Sublancin with Combined Antibacterial and Immunomodulatory Activities to Protect Against Methicillin-Resistant Staphylococcus Aureus Infection in Mice.

Synergetic Antibacterial Nanoparticles with Broad‐Spectrum for Wound Healing and Lung Infection Therapy

Storage stability of lysostaphin solution and its pulmonary delivery

PLGA nanoparticle-encapsulated lysostaphin for the treatment of Staphylococcus aureus infections